Brazilian President Luiz Inácio Lula da Silva said on Monday (Feb. 9) that there will be no shortage of money for health research during his administration. While advocating multilateralism at an event held by the Butantan Institute, Lula also spoke about the partnership with China for vaccine production in Brazil and said he is not choosing the Asian country over the US.

“We are choosing what’s best for our country. If China agrees to partner with us in vaccine production and will produce the quantity we’re not yet able to produce, why not enter into an agreement with China?” he said.

Notícias relacionadas:

• Registration of Brazil’s dengue vaccine officially announced.
• COVID-19 still worrying five years after vaccination started in Brazil.

In São Paulo, the event marked the start of dengue vaccination for primary care health professionals across Brazil. The vaccine, which is produced entirely in Brazil, was developed by Butantan after more than 15 years of research funded by the federal government and the state government of São Paulo.

“As long as I am able to help, there will be no shortage of money for research, either at Butantan or any other research institute in this country,” he noted.
 

The goal is to protect 1.2 million workers on the front lines of Brazil’s national health care system, the SUS, against dengue fever. The expansion of vaccination to other groups, aged 15 to 59, starting with the oldest, is planned for the second half of this year as Butantan expands its production capacity.

Brazil’s Ministry of Health has been purchasing all available supplies, and it is expected that, based on a strategic partnership between Brazil and China, with the transfer of technology to WuXi Vaccines, production could increase 30-fold.

President Lula also spoke about fake news that attempts to discredit the importance of vaccination and stated that it is necessary to convince society to return to vaccination, “as it was in the past.”

“We have an obligation not to get discouraged, to campaign, to talk in schools, to have teachers talk, pastors and priests talk [in churches], politicians talk, until we convince people that getting vaccinated means avoiding the possibility that, at some point, nature [viruses and bacteria] could disrupt a person’s life,” he argued.

For the sixth consecutive month since the Trump administration’s tariff increase, Brazilian exports to the United States have fallen. Sales to China, however, continued to rise, according to data released on Thursday (Feb. 5) in Brasília by the Ministry of Development, Industry, Trade and Services.

In January, sales to the United States totaled USD 2.4 billion, a 25.5 percent decrease compared to USD 3.22 billion in the same month of 2025. Imports of US products fell 10.9 percent to USD 3.07 billion, resulting in a USD 670 million bilateral trade deficit for Brazil.

Notícias relacionadas:

• Brazilian trade balance records second-best January result.

This was the sixth consecutive decline in Brazilian sales to the US since the imposition of the 50 percent surcharge applied by the Donald Trump administration to Brazilian products in mid-2025. Although the tariff was partially revised at the end of last year, the ministry estimates that 22 percent of Brazilian exports are still subject to the extra rates, which vary between 40 percent and 50 percent.

In contrast to the United States, Brazil recorded positive results with China. Brazilian exports to the Asian country grew 17.4 percent in January, totaling USD 6.47 billion, compared to USD 5.51 billion a year earlier. Imports fell 4.9 percent to USD 5.75 billion, ensuring a surplus of USD 720 million for Brazil in the month.

Trade flow

China and the US are Brazil’s main trading partners. The trade flow - the sum of imports and exports - reached USD 12.23 billion, a 5.7 percent increase with China. Trade with the United States totaled USD 5.47 billion, an 18 percent decrease, reflecting reductions in both exports and imports.